Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Most "protein kinases" are enzymes transferring phosphate groups from ATP to specific amino acids (serine, threonine, tyrosine) on protein substrates, regulating activity in key pathways such as signal transduction, cell division, and differentiation. "Tyrosine kinases" specifically phosphorylate tyrosine residues, while "serine/threonine kinases" act on serine and threonine. Some kinases, known as "dual-specificity kinases" (e.g., MAP kinase kinases/MEKs), can phosphorylate both. Aberrant kinase activity is implicated in multiple diseases, notably cancer and autoimmunity, making them major pharmacological targets. The term "Threonine and Tyrosine Kinase" does not accurately refer to a unique canonical target; relevant canonical targets should be "Tyrosine kinase," "Serine/threonine kinase," or precise dual-specificity kinases such as "Mitogen-activated protein kinase kinase (MEK)".
Competitive inhibition of ATP-binding site (for many TKIs); Allosteric inhibition; Covalent inhibition; Type I–V inhibitor classes based on binding site and mechanism
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Threonine and Tyrosine Kinase (None).